Results 121 to 130 of about 28,509 (263)

Efficacy and Safety of Intralymphatic Immunotherapy With Grass Allergoid and Microcrystalline Tyrosine: A Double‐Blind Randomised Placebo‐Controlled Trial

Allergy, EarlyView.
This is the first randomised placebo‐controlled trial of intralymphatic immunotherapy using a microcrystalline tyrosine‐adjuvanted grass pollen allergoid. Three ultrasound‐guided ILIT injections were well tolerated and reduced combined symptom‐medication scores compared with placebo. The findings support further optimisation and clinical development of
Lara Šošić, Stephan C. Flory, Claudia C. V. Lang, Emma C. Widmer, Alexandra Chabot, Johannes M. Schmid, Tobias Andermatt, David Melillo, Bjarke Hviid‐Vyff, Maibritt Mardahl, Peter Schmid‐Grendelmeier, Thomas M. Kündig, Hans Jürgen Hoffmann, Pål Johansen   +13 more
wiley   +1 more source

Cache‐Cache: Dans les souffles du Grand Fleuve…

Anthropology of Consciousness, EarlyView.
ABSTRACT Between ventriloquism and divination, devotion and consecration, an old and sublime marine game unfolds each day, with living breaths shared in the waters of the great river. In Tadoussac, on the north shore of the St. Lawrence Estuary, at the mouth of the Saguenay, the rumor of whales has long resonated.
David Jaclin, Alexis Aubin‐Laperrière, Nicolas Cadieux, Patrick Weldon   +3 more
wiley   +1 more source

Chronic urticaria and quality of life. [PDF]

Bioinformation
Alam R, Vardhan KH, Goel S, Jindal A.
europepmc   +1 more source

Safety and Clinical Outcomes of High‐ Versus Low‐Dose Oral Peanut Immunotherapy in Polish Children With Peanut Allergy

Acta Paediatrica, EarlyView.
ABSTRACT Aim To compare safety and clinical outcomes of two different oral immunotherapy (OIT) maintenance doses (150 mg vs. 300 mg) of peanut protein in children with peanut allergy. Methods This prospective study enrolled 44 children aged 4–17 years with confirmed peanut allergy.
Klementyna Łyżwa, Magdalena Chojnowska‐Wójtowicz, Wioletta Zagórska, Marek Kulus, Katarzyna Grzela   +4 more
wiley   +1 more source

Serum Immunometabolic Biomarkers Reveal Distinct Phenotypes in Chronic Urticaria. [PDF]

Diagnostics (Basel)
Duman N, Muftuoglu C, Tahhan B, Coşkun T, Ece D, Mert U, Özkal S, Caner A.   +7 more
europepmc   +1 more source

Modelling Patterns of Past Inundation Processes Combining Geoarchaeology and Morphometric Hydrological Analysis in the Shashe‐Limpopo Basin, South Africa

Archaeometry, EarlyView.
ABSTRACT Riverine and valley systems across the globe have been central to the development of past urban centres. By AD 900, the Shashe and Limpopo Rivers seem to have facilitated the interaction and integration of early farming communities in southern Africa. This paper focuses on the application of geoarchaeological perspectives made available by the
B. S. Nxumalo
wiley   +1 more source

Treatment response in chronic urticaria: analysis of clinical and laboratory predictors. [PDF]

An Bras Dermatol
Fonseca JTD, Figueiredo JP, Neves LVBT, Oliveira JCS, Oliveira JS, Figueiredo VR, Campos RA.   +6 more
europepmc   +1 more source

Real‐World Outcomes of Omalizumab for Chronic Spontaneous Urticaria in a New Zealand Regional Dermatology Service

Australasian Journal of Dermatology, EarlyView.
Jeffrey Lee, Karen Koch
wiley   +1 more source

Rebound Pruritus and Urticaria After Discontinuation of Chronic Antihistamine Use—A Scoping Review

Clinical &Experimental Allergy, EarlyView.
Rebound pruritus and urticaria have been reported after discontinuation of chronic cetirizine or levocetirizine use only. Symptoms typically occur within 0.5–5 days after stopping therapy and appear more frequently reported in female patients. Re‐initiation of antihistamines is the most commonly effective management strategy, highlighting the need for ...
Jun Jie Benjamin Seng, Prawira Oka, Ngiap Chuan Tan   +2 more
wiley   +1 more source

The Role of Borrelia Burgdorferi in the Etiology of Chronic Urticaria. [PDF]

Med Arch
Krkic-Dautovic S.
europepmc   +1 more source